Singapore’s Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab) for the prevention ...

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public ...

Big shakeups may be coming to the childhood vaccination schedule. Here's a look at some of the shots that could be subject to ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...